Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4529437 | 0.90 | NR3C1 (0.64) | NR3C1MEN1LMNATSHRHTT | |
| SCHEMBL4516017 | 0.84 | NR3C1 (0.61) | NR3C1PGRNR3C2FFAR4ALDH1A1 | |
| SCHEMBL4512209 | 0.84 | NR3C1 (0.64) | NR3C1PGRNR3C2 | |
| SCHEMBL4528546 | 0.82 | NR3C1 (1.00) | NR3C1PGRNR3C2 | |
| SCHEMBL4518114 | 0.79 | NR3C1 (0.55) | NR3C1MEN1LMNATSHRHTT | |
| SCHEMBL4518082 | 0.78 | NR3C1 (0.54) | NR3C1MEN1LMNATSHRHTT | |
| SCHEMBL4517240 | 0.77 | NR3C1 (0.58) | NR3C1MEN1HTTKMT2APGR | |
| SCHEMBL4504090 | 0.76 | NR3C1 (0.60) | NR3C1PGRNR3C2 | |
| SCHEMBL4510346 | 0.76 | NR3C1 (0.60) | NR3C1SMN1; SMN2PGRNR3C2 | |
| SCHEMBL4524659 | 0.76 | NR3C1 (0.62) | NR3C1PGRMTNR1AMTNR1BFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885MEN1 4535/4885LMNA 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.